Myriad(US:MYGN) Globenewswire·2026-01-12 13:30Core Viewpoint - Myriad Genetics, Inc. has announced preliminary financial results for Q4 and full year 2025, along with financial guidance for 2026, indicating growth expectations in revenue and adjusted EBITDA [1][6]. Financial Results - The company anticipates total revenues for Q4 2025 to be between $207 million and $209 million [7]. - For the full year 2025, total revenues are expected to be between $822 million and $824 million [7]. - The preliminary results are subject to finalization and external audit, meaning they may change before the official earnings call in February 2026 [4]. 2026 Financial Guidance - Myriad Genetics projects 2026 revenue guidance to be between $860 million and $880 million, reflecting an approximate 6% increase compared to the mid-point of the preliminary 2025 revenue range [6]. - The adjusted gross margin for 2026 is expected to be between 68% and 69%, incorporating impacts from new product launches [6]. - Adjusted EBITDA for 2026 is projected to be between $37 million and $49 million, indicating an expected growth of approximately 43% over the mid-point of the previous full year 2025 guidance range [6].